Business
Vor Bio to Participate in Upcoming Investor Conferences
BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences: TD Cowen Virtual Immunology & Inflammation SummitFireside Chat: Wednesday, November 12, 2025, at 2:30pm ET 8th Annual Evercore Healthcare ConferenceFireside Chat: Tuesday, December 2, 2025, 3:00pm ETLocation: Miami, FL A live webcast and archived replay of
About this update from Vor Biopharma Inc.
BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences: TD Cowen Virtual Immunology & Inflammation Summit Fireside Chat: Wednesday, November 12, 2025, at 2:30pm ET 8th Annual Evercore Healthcare Conference Fireside Chat: Tuesday, December 2, 2025, 3:00pm ET Location: Miami, FL A live webcast and archived replay of the fireside chats will be available on the investors section of www.vorbio.com . About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com . Media & Investor Contacts: Carl Mauch [email protected] Sarah Spencer [email protected]
View stock analysis, news, and events for Vor Biopharma Inc.